drugset / Trial / NCT02834741
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a first in human study of NYX-2925. It will evaluate single and multiple ascending doses of NYX-2925 in healthy volunteers.
Timeline
- Start
- 2016-07
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NYX-2925 | Small molecule | 50 mg | Oral |
| Comparator | NYX-2925 | Small molecule | 300 mg | Oral |
Indications
No indication recorded.